Otonomy, Inc. (OTIC) Receives Outperform Rating from Cowen and Company
Otonomy, Inc. (NASDAQ:OTIC)‘s stock had its “outperform” rating reissued by equities researchers at Cowen and Company in a research note issued to investors on Wednesday. They currently have a $55.00 target price on the biopharmaceutical company’s stock. Cowen and Company’s price target suggests a potential upside of 170.27% from the company’s current price.
A number of other equities research analysts have also weighed in on OTIC. Zacks Investment Research raised Otonomy from a “sell” rating to a “hold” rating in a research note on Friday, August 18th. BidaskClub lowered Otonomy from a “buy” rating to a “hold” rating in a research note on Friday, August 11th. J P Morgan Chase & Co raised Otonomy from a “neutral” rating to an “overweight” rating and set a $28.00 target price for the company in a research note on Tuesday, August 15th. Finally, Piper Jaffray Companies reissued an “overweight” rating and issued a $32.00 target price on shares of Otonomy in a research note on Friday, June 30th. Two investment analysts have rated the stock with a hold rating and three have given a buy rating to the stock. The stock has an average rating of “Buy” and a consensus price target of $32.50.
Shares of Otonomy (NASDAQ OTIC) traded down 0.25% during mid-day trading on Wednesday, reaching $20.30. The company had a trading volume of 141,446 shares. The firm’s 50-day moving average price is $18.62 and its 200 day moving average price is $15.14. The company’s market cap is $615.15 million. Otonomy has a 52-week low of $11.30 and a 52-week high of $20.65.
Otonomy (NASDAQ:OTIC) last released its earnings results on Thursday, August 3rd. The biopharmaceutical company reported ($0.77) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.80) by $0.03. Otonomy had a negative return on equity of 57.43% and a negative net margin of 8,172.38%. The company had revenue of $0.33 million during the quarter, compared to analyst estimates of $0.43 million. During the same quarter in the previous year, the company posted ($0.98) EPS. Otonomy’s revenue for the quarter was up 312.5% on a year-over-year basis. Equities analysts expect that Otonomy will post ($3.36) EPS for the current year.
In other Otonomy news, insider Eric J. Loumeau sold 3,522 shares of the company’s stock in a transaction that occurred on Monday, June 26th. The stock was sold at an average price of $18.59, for a total transaction of $65,473.98. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Corporate insiders own 12.70% of the company’s stock.
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Geode Capital Management LLC raised its position in Otonomy by 10.6% in the first quarter. Geode Capital Management LLC now owns 207,439 shares of the biopharmaceutical company’s stock worth $2,541,000 after buying an additional 19,804 shares during the last quarter. Vanguard Group Inc. raised its position in Otonomy by 8.8% in the first quarter. Vanguard Group Inc. now owns 1,004,584 shares of the biopharmaceutical company’s stock worth $12,306,000 after buying an additional 81,050 shares during the last quarter. Wellington Management Group LLP raised its position in Otonomy by 28.9% in the first quarter. Wellington Management Group LLP now owns 4,211,357 shares of the biopharmaceutical company’s stock worth $51,590,000 after buying an additional 944,663 shares during the last quarter. American International Group Inc. raised its position in Otonomy by 7.1% in the first quarter. American International Group Inc. now owns 14,800 shares of the biopharmaceutical company’s stock worth $181,000 after buying an additional 981 shares during the last quarter. Finally, Schroder Investment Management Group raised its position in Otonomy by 37.5% in the first quarter. Schroder Investment Management Group now owns 763,368 shares of the biopharmaceutical company’s stock worth $9,351,000 after buying an additional 208,221 shares during the last quarter. 88.46% of the stock is owned by institutional investors and hedge funds.
Otonomy Company Profile
Otonomy, Inc is a biopharmaceutical company. The Company focuses on the development and commercialization of therapeutics for diseases and disorders of the ear. The Company’s product candidates include OTIPRIO, OTO-104 and OTO-311. OTIPRIO is a single-dose, physician-administered antibacterial, which is used for the treatment of pediatric patients with bilateral otitis media with effusion undergoing tympanostomy tube placement (TTP) surgery and is available for commercial purchase.
Receive News & Ratings for Otonomy Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Otonomy Inc. and related companies with MarketBeat.com's FREE daily email newsletter.